论文部分内容阅读
为探讨乳腺癌Ｃ－ｅｒｂＢ－２癌基因与雌激素和孕激素受体的关系及其临床意义，采用ＬＳＡＢ免疫组化法对１０６例乳腺癌标本进行Ｃ－ｅｒｂＢ－２癌基因的检测。结果：Ｃ－ｅｂｒＢ－２表达阳性率为６３．２％（６７／１０６），对生存时间≤５年及＞１０年者，其Ｃ－ｅｒｂＢ－２表达阳性率分别为８１．６３％和３４．２９％，表明Ｃ－ｅｒｂＢ－２癌基因过度表达与乳腺癌的临床分期晚、组织学分级高、腋窝淋巴结转移有关，并与雌激素、孕激素受体状况呈负相关。由此提示Ｃ－ｅｒｂＢ－２癌基因的过度表达是判断乳腺癌预后的一个重要因素，宜将Ｃ－ｅｒｂＢ－２癌基因列为乳腺癌的常规检测指标之一。
In order to investigate the relationship between C-erbB-2 oncogene and estrogen and progesterone receptors in breast cancer, LSAB immunohistochemistry was used to detect C-erbB-2 oncogene in 106 breast cancer specimens. RESULTS: The positive rate of C-ebrB-2 expression was 63.2% (67/106). The positive rate of C-erbB-2 expression was 81.63% and 34% for patients whose survival time was ≤5 years and >10 years, respectively. .29%, indicating that overexpression of C-erbB-2 oncogene is associated with late clinical stage, high histological grade, axillary lymph node metastasis, and negative correlation with estrogen and progesterone receptor status. This suggests that overexpression of C-erbB-2 oncogene is an important factor in judging the prognosis of breast cancer, and C-erbB-2 oncogene should be listed as one of the routine detection criteria for breast cancer.